Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: Filling the gaps.
Level 5 - mechanism / opinion, no new human data
Narrative review of clinical trial substudies without a formal systematic review or meta-analysis methodology
PubMed 39344838 · doi:10.1111/dom.15913
What was done
The authors reviewed 28 clinical trials evaluating changes in fat-free mass (FFM) associated with the GLP-1 receptor agonists exenatide, liraglutide, semaglutide, and the dual incretin agonist tirzepatide. Body composition changes measured by dual-energy X-ray absorptiometry (DXA) were evaluated, and the percentage of total weight loss occurring as fat-free mass (%FFML, calculated as ΔFFM/total weight change) was compared against reference benchmarks from dietary restriction (<25% FFM loss) and metabolic bariatric surgery.
What was found
The %FFML across GLP-1RA-based interventions ranged from 20% to 40%. While the proportion of FFM reduction was highly variable across the 28 clinical trials, the majority reported %FFML exceeding 25%.
Why it matters
As GLP-1RA-based therapies become standard for type 2 diabetes and obesity, understanding whether lean mass reduction exceeds that of typical caloric restriction is clinically important. This review indicates that lean mass loss frequently surpasses 25% of total weight loss, highlighting the need to evaluate skeletal muscle preservation and functional outcomes.
Limits
The analysis was limited to small trial substudies and relied exclusively on DXA, which does not measure skeletal muscle mass directly (skeletal muscle comprises only ~55% of FFM). Muscle quality and physical function were not assessed, and total participant counts across trials were not provided in the abstract.
Cited by
- supports Skeletal muscle accounts for approximately 50% of total lean body mass.